{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:07:16Z","timestamp":1790132836379,"version":"4.0.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020986","name":"Innate Pharma","doi-asserted-by":"publisher","award":["NCT04563923"],"award-info":[{"award-number":["NCT04563923"]}],"id":[{"id":"10.13039\/100020986","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013371","name":"Universit\u00e9 C\u00f4te d'Azur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013371","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.xjidi.2024.100307","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T18:47:46Z","timestamp":1724438866000},"page":"100307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Treatment of Bullous Pemphigoid with Avdoralimab: Multicenter, Randomized, Open-Labeled Phase 2 Study"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0797-6570","authenticated-orcid":false,"given":"Thierry","family":"Passeron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1849-9626","authenticated-orcid":false,"given":"Eric","family":"Fontas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5855-1537","authenticated-orcid":false,"given":"Thierry","family":"Boye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0870-9132","authenticated-orcid":false,"given":"Marie-Aleth","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7057-0998","authenticated-orcid":false,"given":"Emmanuel","family":"Delaporte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8736-1922","authenticated-orcid":false,"given":"Olivier","family":"Dereure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2024.100307_bib1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12016-017-8633-4","article-title":"Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management","volume":"54","author":"Amber","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.xjidi.2024.100307_bib2","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1097\/CCM.0000000000005683","article-title":"Avdoralimab (anti-C5aR1 mAb) versus placebo in patients with severe COVID-19: results from a randomized controlled trial (FOR COVID elimination [FORCE])","volume":"50","author":"Carvelli","year":"2022","journal-title":"Crit Care Med"},{"key":"10.1016\/j.xjidi.2024.100307_bib3","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1172\/JCI11494","article-title":"Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid","volume":"108","author":"Chen","year":"2001","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.xjidi.2024.100307_bib4","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.3389\/fimmu.2019.01477","article-title":"Complement activation in autoimmune bullous dermatoses: a comprehensive review","volume":"10","author":"Edwards","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.xjidi.2024.100307_bib5","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1074\/jbc.M111.221036","article-title":"The C5a receptor on mast cells is critical for the autoimmune skin-blistering disease bullous pemphigoid","volume":"286","author":"Heimbach","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.xjidi.2024.100307_bib6","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100307_bib7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3389\/fimmu.2018.00488","article-title":"Tissue destruction in bullous pemphigoid can be complement independent and may be mitigated by C5aR2","volume":"9","author":"Karsten","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.xjidi.2024.100307_bib8","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/1346-8138.14503","article-title":"Mortality in bullous pemphigoid: a systematic review and meta-analysis of standardized mortality ratios","volume":"45","author":"Kridin","year":"2018","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.xjidi.2024.100307_bib9","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/archdermatol.2012.2994","article-title":"Mortality of bullous pemphigoid in China","volume":"149","author":"Li","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2024.100307_bib10","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1172\/JCI119639","article-title":"A\u00a0major role for neutrophils in experimental bullous pemphigoid","volume":"100","author":"Liu","year":"1997","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.xjidi.2024.100307_bib11","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2008.07.022","article-title":"Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States","volume":"59","author":"Parker","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2024.100307_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/path.6220","article-title":"Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A\/NC15A extracellular domains is driven by Fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockade","volume":"262","author":"Pigors","year":"2024","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.xjidi.2024.100307_bib13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jamadermatol.2022.1156","article-title":"Evaluation of nomacopan for treatment of bullous pemphigoid: a phase 2a nonrandomized controlled trial","volume":"158","author":"Sadik","year":"2022","journal-title":"JAMA Dermatol"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026724000547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026724000547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T06:25:10Z","timestamp":1731738310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026724000547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2667026724000547"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2024.100307","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Bullous Pemphigoid with Avdoralimab: Multicenter, Randomized, Open-Labeled Phase 2 Study","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2024.100307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100307"}}